title: Cutaneous zygomycosis in an infant with Pearson syndrome.
authors.forename: Kalomoira
authors.initials: K
authors.lastname: Kefala-Agoropoulou
authors.forename: Evangelia
authors.initials: E
authors.lastname: Farmaki
authors.forename: John
authors.initials: J
authors.lastname: Tsiouris
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Roilides
authors.forename: Aristea
authors.initials: A
authors.lastname: Velegraki
mesh_terms: D000666:Amphotericin B / Q000627:therapeutic use; D000751:Anemia, Neonatal / Q000209:etiology / Q000473:pathology; D000756:Anemia, Sideroblastic / Q000209:etiology / Q000473:pathology; D000935:Antifungal Agents / Q000627:therapeutic use; D002408:Catheters, Indwelling / Q000009:adverse effects*; D004272:DNA, Mitochondrial; D003676:Deferoxamine / Q000627:therapeutic use; D003881:Dermatomycoses / Q000188:drug therapy / Q000209:etiology / Q000473:pathology*; D005260:Female; D000071020:Hemochromatosis Protein; D006579:Heterozygote; D015395:Histocompatibility Antigens Class I / Q000235:genetics; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008565:Membrane Proteins / Q000235:genetics; D008659:Metabolic Diseases / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D008775:Methylprednisolone / Q000627:therapeutic use; D028361:Mitochondrial Diseases / Q000473:pathology; D017262:Siderophores / Q000627:therapeutic use; D020096:Zygomycosis / Q000188:drug therapy / Q000209:etiology / Q000473:pathology*
chemical_list: D000935:Antifungal Agents; D004272:DNA, Mitochondrial; C103673:HFE protein, human; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I; D008565:Membrane Proteins; D017262:Siderophores; C068538:liposomal amphotericin B; D000666:Amphotericin B; D003676:Deferoxamine; D008775:Methylprednisolone